Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.
From Product Candidate to Product: The Road to Commercialization in Regenerative Medicine
Although few cell therapies are currently available to patients, Cell Therapy Group estimates that there are 37 cell therapies currently in late stage clinical development. [i] Many of these are likely to be positioned for ... Continued